Remove 2023 Remove Biosimilars Remove Diabetes
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

article thumbnail

MHRA approves biosimilar for vision disorders in Great Britain

European Pharmaceutical Review

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Ximluci ® (ranibizumab), a biosimilar referencing Lucentis®, to help treat a leading cause of blindness globally. A biosimilar for biologic ophthalmic treatments. STADA is preparing to launch Ximluci ® in the UK during 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biosimilar Clinical Trial Updates

Big Molecule Watch

On May 4, 2023, Alvotech announced the initiation of a confirmatory patient study for AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab). On May 15, 2023, Boan Biotech announced the completion of patient enrollment for a Phase III clinical trial of the company’s Dulaglutide Injection (BA5101) in China.

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs. Similarly, Dr. Reddy’s and Cipla are exploring the biosimilar and complex generics space, focusing on areas like respiratory and oncology drugs.

article thumbnail

Biocon Biologics gets positive CHMP opinion for YESAFILI, biosimilar Aflibercept

Express Pharma

Biocon Biologics, a subsidiary of Biocon announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESAFILI, an aflibercept biosimilar. The European Commission decision on the approval is expected by the end of September 2023.

article thumbnail

Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData

Express Pharma

Despite the continued inflationary pressures, the second quarter (Q2) of 2023 yielded promising outcomes for the leading 20 biopharma giants. trillion during the first quarter (Q1) of 2023 to an impressive $3.56 trillion in Q2 2023, reveals GlobalData. per cent) recording negative growth exceeding 10 per cent in Q2 2023.

article thumbnail

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Express Pharma

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.

Diabetes 105